Mostrar el registro sencillo del ítem

dc.contributor.authorFuentes-Abolafio, Iván José
dc.contributor.authorRicci, Michel
dc.contributor.authorBernal López, María Rosa
dc.contributor.authorGómez-Huelgas, Ricardo 
dc.contributor.authorCuesta-Vargas, Antonio 
dc.contributor.authorPérez-Belmonte, Luis Miguel 
dc.date.accessioned2022-09-27T11:25:20Z
dc.date.available2022-09-27T11:25:20Z
dc.date.issued2022-08-08
dc.identifier.citationFuentes-Abolafio, I.J., Ricci, M., Bernal-López, M.R. et al. Biomarkers and the quadriceps femoris muscle architecture assessed by ultrasound in older adults with heart failure with preserved ejection fraction: a cross-sectional study. Aging Clin Exp Res (2022). https://doi.org/10.1007/s40520-022-02189-7es_ES
dc.identifier.urihttps://hdl.handle.net/10630/25101
dc.description.abstractBackground: Sarcopenia is an important comorbidity in patients with heart failure with preserved ejection fraction (HFpEF). The ultrasound (US) assessment has all the advantages of being used in primary care to assess muscle quantity and quality. Some biomarkers could be indicative of muscle mass loss. Aims: To describe the quantitative and qualitative characteristics of the quadriceps femoris assessed by US in older adults with HFpEF and to assess the relationship of the blood and urinary biomarkers, the polypharmacy and comorbidities with US outcomes in older adults with HFpEF. Methods: A cross-sectional study was conducted. 76 older adults with HFpEF were included. The quadriceps femoris muscle thickness (MT, cm), the subcutaneous fat tissue thickness (FT, cm), the muscle echo intensity (MEI) and the subcutaneous fat tissue echo intensity (FEI) were assessed by US in a non-contraction (non-con) and contraction (con) situations. Polypharmacy, comorbidities, blood and urine biomarkers were also collected. Results: The carbohydrate antigen 125 (CA-125), the folic acid and the urine creatinine shared the 86.6% variance in the non-con MT, adjusted by age, sex and body mass index (BMI). The folic acid shared the 38.5% of the variance in the con MT, adjusted by age, sex and BMI. The glycosylated haemoglobin explained the 39.6% variance in the non-con MEI, adjusted by age, sex and BMI. The chlorine (Cl−) explained the 40.2% of the variance in the non-con FT, adjusted by age, sex and BMI. The polypharmacy and the folic acid explained the 37.9% of variance in the non-con FEI, while the polypharmacy and the thyrotropin (TSH) shared the 44.4% of variance in the con FEI, both adjusted by age, sex and BMI. No comorbidities, polypharmacy, or blood and urinary biomarkers could explain the con MEI and the con FT variance. Conclusions: (...)es_ES
dc.description.sponsorshipOpen Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. Funding for open access charge: Universidad de Málaga / CBUA. This work was supported by the Spanish Foundation of Internal Medicine, through the call “PROF. DR. MIGUEL VILARDELL 2019 research project”. Grant number: FEMI-PB-PI-MV-2019.es_ES
dc.language.isospaes_ES
dc.publisherSpringeres_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectInsuficiencia cardíacaes_ES
dc.subject.otherBlood biomarkerses_ES
dc.subject.otherHeart failurees_ES
dc.subject.otherMuscle thicknesses_ES
dc.subject.otherOlder adultses_ES
dc.subject.otherUltrasoundes_ES
dc.subject.otherUrinary biomarkerses_ES
dc.titleBiomarkers and the quadriceps femoris muscle architecture assessed by ultrasound in older adults with heart failure with preserved ejection fraction: a cross-sectional studyes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.centroFacultad de Medicinaes_ES
dc.identifier.doihttps://doi.org/10.1007/s40520-022-02189-7
dc.rights.ccAtribución 4.0 Internacional*
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional